Story March 20 - Elevation Oncology: The biotech is ditching its sole clinical-stage asset in the wake of disappointing phase 1 data and laying off 70% of its staff as a result. The restructuring ...

Real time quote data is not available at this time. *Data is provided by Barchart.com. Data reflects weightings calculated at the beginning of each month. Data is subject to change. **Green ...